Muscle Atrophy - Pipeline Review, H1 2014
Muscle Atrophy - Pipeline Review, H1 2014
Summary
Global Markets Directs, Muscle...
muscle Atrophy - Products Under Development By Companies 14
muscle Atrophy - Products Under Investigation By Universities/...
Upcoming SlideShare
Loading in …5
×

Muscle Atrophy - Pipeline Review, H1 2014: Market Trends and Forecast

261 views

Published on

Muscle Atrophy - Pipeline Review, H1 2014 @ http://www.researchmoz.us/muscle-atrophy-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Healthcare
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
261
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Muscle Atrophy - Pipeline Review, H1 2014: Market Trends and Forecast

  1. 1. Muscle Atrophy - Pipeline Review, H1 2014 Muscle Atrophy - Pipeline Review, H1 2014 Summary Global Markets Directs, Muscle Atrophy - Pipeline Review, H1 2014, provides an overview of the Muscle Atrophys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Muscle Atrophy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Muscle Atrophy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 4 introduction 5 global Markets Direct Report Coverage 5 muscle Atrophy Overview 6 therapeutics Development 7 pipeline Products For Muscle Atrophy - Overview 7 pipeline Products For Muscle Atrophy - Comparative Analysis 8 muscle Atrophy - Therapeutics Under Development By Companies 9 muscle Atrophy - Therapeutics Under Investigation By Universities/institutes 11 muscle Atrophy - Pipeline Products Glance 12 clinical Stage Products 12 early Stage Products 13 Muscle Atrophy - Pipeline Review, H1 2014
  2. 2. muscle Atrophy - Products Under Development By Companies 14 muscle Atrophy - Products Under Investigation By Universities/institutes 15 muscle Atrophy - Companies Involved In Therapeutics Development 16 eli Lilly And Company 16 rigel Pharmaceuticals, Inc. 17 fate Therapeutics, Inc. 18 muscle Atrophy - Therapeutics Assessment 19 assessment By Monotherapy Products 19 assessment By Target 20 assessment By Mechanism Of Action 22 assessment By Route Of Administration 24 assessment By Molecule Type 26 drug Profiles 28 ly-2495655 - Drug Profile 28 product Description 28 mechanism Of Action 28 r&d Progress 28 drug For Muscle Atrophy - Drug Profile 29 product Description 29 mechanism Of Action 29 r&d Progress 29 atropy Inhibitor - Drug Profile 30 product Description 30 mechanism Of Action 30 r&d Progress 30 ft-301 - Drug Profile 31 product Description 31 mechanism Of Action 31 r&d Progress 31 wnt7a-based Protein Thearpeutics - Drug Profile 33 product Description 33 mechanism Of Action 33 r&d Progress 33 l-379 - Drug Profile 35 product Description 35 mechanism Of Action 35 r&d Progress 35 muscle Atrophy - Recent Pipeline Updates 36 muscle Atrophy - Dormant Projects 37 appendix 38 methodology 38 coverage 38 secondary Research 38 primary Research 38 expert Panel Validation 38 contact Us 39 disclaimer 39 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Muscle Atrophy - Pipeline Review, H1 2014

×